Daniel J. Booser, MD, FRCPC

Peer-Reviewed Articles

1. Lim B, Murthy RK, Lee J, Jackson SA, Iwase T, Davis DW, Willey JS, Wu J, Shen Y, Tripathy D, Alvarez R, Ibrahim NK, Brewster AM, Barcenas CH, Brown PH, Giordano SH, Moulder SL, Booser DJ, Moscow JA, Piekarz R, Valero V, Ueno NT. A phase Ib study of entinostat plus lapatinib with or without trastuzumab in patients with HER2-positive metastatic breast cancer that progressed during trastuzumab treatment. Br J Cancer 120(12):1105-1112, 2019. e-Pub 2019. PMID: 31097774.
2. Yam C, Murthy RK, Rauch GM, Murray JL, Walters RS, Valero V, Brewster AM, Bast RC, Booser DJ, SH, Esteva FJ, Yang W, Hortobagyi GN, Moulder SL, Arun B. A phase II study of imatinib mesylate and letrozole in patients with hormone receptor-positive metastatic breast cancer expressing c-kit or PDGFR-β. Invest New Drugs 36(6):1103-1109, 2018. e-Pub 2018. PMID: 30311036.
3. Moulder S, Helgason T, Janku F, Wheler J, Moroney J, Booser DJ, Albarracin C, Morrow PK, Atkins J, Koenig K, Gilcrease M, Kurzrock R. Inhibition of the phosphoinositide 3-kinase pathway for the treatment of patients with metastatic metaplastic breast cancer. Ann Oncol 26(7):1346-52, 2015. e-Pub 2015. PMID: 25878190.
4. Murthy RK, Varma A, Mishra P, Hess KR, Young E, Murray JL, Koenig KH, Moulder SL, Melhem-Bertrandt A, Giordano SH, Booser DJ, V, Hortobagyi GN, Esteva FJ. Effect of adjuvant/neoadjuvant trastuzumab on clinical outcomes in patients with HER2-positive metastatic breast cancer. Cancer 120(13):1932-8, 2014. e-Pub 2014. PMID: 24677057.
5. Eckmann K, Michaud LB, Rivera E, Madden TL, Esparza-Guerra L, Kawedia J, Booser DJ, Green MC, Hortobagyi GN, Valero V. Pilot study to assess toxicity and pharmacokinetics of docetaxel in patients with metastatic breast cancer and impaired liver function secondary to hepatic metastases. J Oncol Pharm Pract 20(2):120-9, 2014. e-Pub 2013. PMID: 23676510.
6. Bayraktar S, Gutierrez-Barrera AM, Lin H, Elsayegh N, Tasbas T, Litton JK, Ibrahim NK, Morrow PK, Green M, Valero V, Booser DJ, Hortobagyi GN, Arun BK. Outcome of metastatic breast cancer in selected women with or without deleterious BRCA mutations. Clin Exp Metastasis 30(5):631-42. e-Pub 2013. PMID: 23370825.
7. Dean-Colomb W, Hess KR, Young E, Gornet TG, Handy BC, Moulder SL, Ibrahim N, Pusztai L, Booser D, Valero V, Hortobagyi GN, Esteva FJ. Elevated serum P1NP predicts development of bone metastasis and survival in early-stage breast cancer. Breast Cancer Res Treat 137(2):631-6, 2013. e-Pub 2012. PMID: 23242617.
8. Skinner HD, Strom EA, Motwani SB, Woodward WA, Green MC, Babiera G, Booser DJ, Meric-Bernstam F, Buchholz TA. Radiation dose escalation for loco-regional recurrence of breast cancer after mastectomy. Radiat Oncol 8(13):2-9, 2013. PMID: 23311297.
9. Santarpia L, Qi Y, Stemke-Hale K, Wang B, Young EJ, Booser DJ, Holmes FA, O'Shaughnessy J, Hellerstedt B, Pippen J, Vidaurre T, Gomez H, Valero V, Hortobagyi GN, Symmans WF, Bottai G, Di Leo A, Gonzalez-Angulo AM, Pusztai L. Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers. Breast Cancer Res Treat 134(1):333-43, 2012. e-Pub 2012. PMID: 22538770.
10. Kelly CM, Green MC, Broglio K, Thomas ES, Brewster AM, Valero V, Ibrahim NK, Gonzalez-Angulo AM, Booser DJ, Walters RS, Hunt KK, Hortobagyi GN, Buzdar AU. Phase III trial evaluating weekly paclitaxel versus docetaxel in combination with capecitabine in operable breast cancer. J Clin Oncol 30(9):930-5, 2012. e-Pub 2012. PMID: 22331946.
11. Moulder S, Gladish G, Ensor J, Gonzalez-Angulo AM, Cristofanilli M, Murray JL, Booser DJ, Giordano SH, Brewster A, Moore J, Rivera E, Hortobagyi GN, Tran HT. A phase 1 study of weekly everolimus (RAD001) in combination with docetaxel in patients with metastatic breast cancer. Cancer 118(9):2378-84, 2012. e-Pub 2011. PMID: 22006179.
12. Iwamoto T, Booser DJ, Valero V, Murray JL, Koenig K, Esteva FJ, Ueno NT, Zhang J, Shi W, Qi Y, Matsuoka J, Yang EJ, Hortobagyi GN, Hatzis C, Symmans WF, Pusztai L. Estrogen receptor mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry. J Clin Oncol 30(7):729-34, 2012. PMID: 22291085.
13. Morrow PK, Wulf GM, Ensor J, Booser DJ, Moore JA, Flores PR, Xiong Y, Zhang S, Krop IE, Winer EP, Kindelberger DW, Coviello J, Sahin AA, Nuñez R, Hortobagyi GN, Yu D, Esteva FJ. Phase I/II Study of Trastuzumab in Combination With Everolimus (RAD001) in Patients With HER2-Overexpressing Metastatic Breast Cancer Who Progressed on Trastuzumab-Based Therapy. J Clin Oncol 29(23):3126-32, 2011. e-Pub 2011. PMID: 21730275.
14. Hatzis C, Pusztai L, Valero V, Booser DJ, Esserman L, Lluch A, Vidaurre T, Holmes F, Souchon E, Wang H, Martin M, Cotrina J, Gomez H, Hubbard R, Chacón JI, Ferrer-Lozano J, Dyer R, Buxton M, Gong Y, Wu Y, Ibrahim N, Andreopoulou E, Ueno NT, Hunt K, Yang W, Nazario A, DeMichele A, O'Shaughnessy J, Hortobagyi GN, Symmans WF. A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. JAMA 305(18):1873-81, 2011. PMID: 21558518.
15. Iwamoto T, Bianchini G, Booser D, Qi Y, Coutant C, Shiang CY, Santarpia L, Matsuoka J, Hortobagyi GN, Symmans WF, Holmes FA, O'Shaughnessy J, Hellerstedt B, Pippen J, Andre F, Simon R, Pusztai L. Gene pathways associated with prognosis and chemotherapy sensitivity in molecular subtypes of breast cancer. J Natl Cancer Inst 103(3):264-72, 2011. e-Pub 2010. PMID: 21191116.
16. Moulder S, Moroney J, Helgason T, Wheler J, Booser D, Albarracin C, Morrow PK, Koenig K, Kurzrock R. Responses to Liposomal Doxorubicin, Bevacizumab, and Temsirolimus in Metaplastic Carcinoma of the Breast: Biologic Rationale and Implications for Stem-Cell Research in Breast Cancer. J Clin Oncol 29(19):e572-5, 2011. e-Pub 2011. PMID: 21482991.
17. Symmans WF, Hatzis C, Sotiriou C, Andre F, Peintinger F, Regitnig P, Daxenbichler G, Desmedt C, Domont J, Marth C, Delaloge S, Bauernhofer T, Valero V, Booser DJ, Hortobagyi GN, Pusztai L. Genomic Index of Sensitivity to Endocrine Therapy for Breast Cancer. J Clin Oncol 28(27):4111-4119, 2010. e-Pub 2010. PMID: 20697068.
18. Alvarez RH,Booser DJ, Cristofanilli M, Sahin AA, Strom EA, Guerra L, Kau SW, Gonzalez-Angulo AM, Hortobagyi GN, Valero V. Phase 2 trial of primary systemic therapy with doxorubicin and docetaxel followed by surgery, radiotherapy, and adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil based on clinical and pathologic response in patients with stage IIB to III breast cancer : long-term results from the University of Texas M. D. Anderson Cancer Center Study ID97-099. Cancer 116(5):1210-7, 2010. PMID: 20082452.
19. Hortobagyi GN, Heim W, Hutchins L, Rivera E, Mason B, Booser DJ, Kirshner J. A phase 2 study of a fixed combination of uracil and ftorafur (UFT) and leucovorin given orally in a 3-times-daily regimen to treat patients with recurrent metastatic breast cancer. Cancer 116(6):1440-5, 2010. PMID: 20091835.
20. Popovici V, Chen W, Gallas BG, Hatzis C, Shi W, Samuelson FW, Nikolsky Y, Tsyganova M, Ishkin A, Nikolskaya T, Hess KR, Valero V, Booser D, Delorenzi M, Hortobagyi GN, Shi L, Symmans WF, Pusztai L. Effect of training-sample size and classification difficulty on the accuracy of genomic predictors. Breast Cancer Res 12(1):R5, 2010. e-Pub 2010. PMID: 20064235.
21. Ueno NT, de Souza JA, Booser DJ, Nakayama K, Madewell J, Wendt RE, Hortobagyi GN, Podoloff D, Champlin RE. Pilot study of targeted skeletal radiation therapy for bone-only metastatic breast cancer. Clin Breast Cancer 9(3):173-7, 2009. PMID: 19661041.
22. Gonzalez-Angulo AM, Walters R, Broglio K, Frye DK, Strom EA, Theriault RL, Booser DJ, Valero V, Buzdar AU, Hortobagyi GN. Using response to primary chemotherapy to select postoperative therapy: long-term results from a prospective phase II trial in locally advanced primary breast cancer. Clin Breast Cancer 8(6):516-21, 2008. PMID: 19073507.
23. Moulder SL, Symmans WF, Booser DJ, Madden TL, Lipsanen C, Yuan L, Brewster AM, Cristofanilli M, Hunt KK, Buchholz TA, Zwiebel J, Valero V, Hortobagyi GN, Esteva FJ. Phase I/II study of G3139 (Bcl-2 antisense oligonucleotide) in combination with doxorubicin and docetaxel in breast cancer. Clin Cancer Res 14(23):7909-16, 2008. PMID: 19047121.
24. Brewster AM, Hortobagyi GN, Broglio KR, Kau SW, Santa-Maria CA, Arun B, Buzdar AU, Booser DJ, Valero V, Bondy M, Esteva FJ. Residual risk of breast cancer recurrence 5 years after adjuvant therapy. J Natl Cancer Inst 100(16):1179-83, 2008. e-Pub 2008. PMID: 18695137.
25. Cristofanilli M, Morandi P, Krishnamurthy S, Reuben JM, Lee BN, Francis D, Booser DJ, Green MC, Arun BK, Pusztai L, Lopez A, Islam R, Valero V, Hortobagyi GN. Imatinib mesylate (Gleevec) in advanced breast cancer-expressing C-Kit or PDGFR-beta: clinical activity and biological correlations. Ann Oncol 19(10):1713-9, 2008. e-Pub 2008. PMID: 18515258.
26. Beinart GA, Gonzalez-Angulo AM, Broglio K, Frye D, Walters R, Holmes FA, Gunale S, Booser D, Rosenthal J, Dhingra K, Young JA, Hortobagyi GN. Phase II trial of 10-EDAM in the treatment of metastatic breast cancer. Cancer Chemother Pharmacol 60:61-7, 2007. e-Pub 2006. PMID: 17009032.
27. Gong Y, Yan K, Lin F, Anderson K, Sotiriou C, Andre F, Holmes FA, Valero V, Booser D, Pippen JE Jr, Vukelja S, Gomez H, Mejia J, Barajas LJ, Hess KR, Sneige N, Hortobagyi GN, Pusztai L, Symmans WF. Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study. Lancet Oncol 8:203-11, 2007. PMID: 17329190.
28. Hanrahan EO, Broglio K, Frye D, Buzdar AU, Theriault RL, Valero V, Booser DJ, Singletary SE, Strom EA, Gajewski JL, Champlin RE, Hortobagyi GN. Randomized trial of high-dose chemotherapy and autologous hematopoietic stem cell support for high-risk primary breast carcinoma: follow-up at 12 years. Cancer 106:2327-36, 2006. PMID: 16639731.
29. Yang CH, Gonzalez-Angulo AM, Reuben JM,Booser DJ, Pusztai L, Krishnamurthy S, Esseltine D, Stec J, Broglio KR, Islam R, Hortobagyi GN, Cristofanilli M. Bortezomib (VELCADE(R)) in metastatic breast cancer: pharmacodynamics, biological effects, and prediction of clinical benefits. Ann Oncol 17:813-7, 2006. PMID: 16403809.
30. Cristofanilli M, Krishnamurthy S, Guerra L, Broglio K, Arun B, Booser DJ, Menander K, Van Wart Hood J, Valero V, Hortobagyi GN. A nonreplicating adenoviral vector that contains the wild-type p53 transgene combined with chemotherapy for primary breast cancer: safety, efficacy, and biologic activity of a novel gene-therapy approach. Cancer 107:935-44, 2006.
31. Hess KR, Anderson K, Symmans WF, Valero V, Ibrahim N, Mejia JA, Booser D, Theriault RL, Buzdar AU, Dempsey PJ, Rouzier R, Sneige N, Ross JS, Vidaurre T, Gómez HL, Hortobagyi GN, Pusztai L. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol 24:4236-44, 2006.
32. Gong Y, Booser DJ, Sneige N. Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma. Cancer 103:1763-9, 2005. PMID: 15786420.
33. Montero A, Booser DJ, Esparza-Guerra L, Murray J, Rosales M, Hortobagyi G, Valero V. Phase I trial of dose-dense docetaxel and doxorubicin with or without sargramostim in patients with metastatic breast cancer. Drugs R D 6:299-305, 2005. PMID: 16128600.
34. Assikis V, Buzdar A, Yang Y, Smith T, Theriault R, Booser D, Valero V, Walters R, Singletary E, Ames F, Hortobagyi G. A phase III trial of sequential adjuvant chemotherapy for operable breast carcinoma: final analysis with 10-year follow-up. Cancer 97:2716-23, 2003. PMID: 12767083.
35. Pusztai L, Ayers M, Stec J, Clark E, Hess K, Stivers D, Damokosh A, Sneige N, Buchholz TA, Esteva FJ, Arun B, Cristofanilli M, Booser D, Rosales M, Valero V, Adams C, Hortobagyi GN, Symmans WF. Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumors. Clin Cancer Res 9:2406-15, 2003. PMID: 12855612.
36. Trent JC, Valero V, Booser DJ, Esparza-Guerra LT, Ibrahim N, Rahman Z, Vernillet L, Patel S, David CL, Murray JL, Cristofanilli M, Hortobagyi GN. A Phase I study of docetaxel plus cyclophosphamide in solid tumors followed by a Phase II study as first-line therapy in metastatic breast cancer. Clin Cancer Res 9:2426-34, 2003. PMID: 12855614.
37. Booser DJ, Esteva FJ, Rivera E, Valero V, Esparza-Guerra L, Priebe W, Hortobagyi GN. Phase II study of liposomal annamycin in the treatment of doxorubicin-resistant breast cancer. Cancer Chemother Pharmacol 50:6-8, 2002. PMID: 12111105.
38. Buzdar AU, Singletary SE, Valero V,Booser DJ, Ibrahim NK, Rahman Z, Theriault RL, Walters R, Rivera E, Smith TL, Holmes FA, Hoy E, Frye DK, Manuel N, Kau SW, McNeese MD, Strom E, Thomas E, Hunt K, Ames F, Berry D, Hortobagyi GN. Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial. Clin Cancer Res 8:1073-9, 2002. PMID: 12006521.
39. Esmaeli B, Hortobagyi G, Esteva F, Valero V, Ahmadi MA, Booser D, Ibrahim N, Delpassand E, Arbuckle R. Canalicular stenosis secondary to weekly docetaxel: a potentially preventable side effect. Ann Oncol 13:218-21, 2002. PMID: 11885997.
40. Esmaeli B, Hortobagyi GN, Esteva FJ, Booser D, Ahmadi MA, Rivera E, Arbuckle R, Delpassand E, Guerra L, Valero V. Canalicular stenosis secondary to weekly versus every-3-weeks docetaxel in patients with metastatic breast cancer. Ophthalmology 109:1188-91, 2002. PMID: 12045065.
41. Esteva FJ, Valero V, Booser DJ, Guerra LT, Murray JL, Pusztai L, Cristofanilli M, Arun B, Esmaeli B, Fritsche HA, Sneige N, Smith TL, Hortobagyi GN. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 20:1800-8, 2002. PMID: 11919237.
42. Giordano SH, Booser DJ, Murray JL, Ibrahim NK, Rahman ZU, Valero V, Theriault RL, Rosales MF, Rivera E, Frye D, Ewer M, Ordonez NG, Buzdar AU, Hortobagyi GN. A detailed evaluation of cardiac toxicity: a phase II study of doxorubicin and one- or three-hour-infusion paclitaxel in patients with metastatic breast cancer. Clin Cancer Res 8:3360-8, 2002. PMID: 12429622.
43. Murray JL, Gillogly ME, Przepiorka D, Brewer H, Ibrahim NK, Booser DJ, Hortobagyi GN, Kudelka AP, Grabstein KH, Cheever MA, Ioannides CG. Toxicity, immunogenicity, and induction of E75-specific tumor-lytic CTLs by HER-2 peptide E75 (369-377) combined with granulocyte macrophage colony-stimulating factor in HLA-A2+ patients with metastatic breast and ovarian cancer. Clin Cancer Res 8:3407-18, 2002. PMID: 12429628.
44. Rivera E, Valero V, Cristofanilli M, Frye DK, Booser DJ, Rosales MM, Hortobagyi GN. Phase I study of eniluracil and oral 5-fluorouracil in combination with docetaxel in the treatment of patients with metastatic breast carcinoma. Cancer 94:2321-6, 2002. PMID: 12015755.
45. Rivera E, Valero V, Esteva FJ, Syrewicz L, Cristofanilli M, Rahman Z, Booser DJ, Hortobagyi GN. Lack of activity of stealth liposomal doxorubicin in the treatment of patients with anthracycline-resistant breast cancer. Cancer Chemother Pharmacol 49:299-302, 2002. PMID: 11914909.
46. Brito RA, Valero V, Buzdar AU, Booser DJ, Ames F, Strom E, Ross M, Theriault RL, Frye D, Kau SW, Asmar L, McNeese M, Singletary SE, Hortobagyi GN. Long-term results of combined-modality therapy for locally advanced breast cancer with ipsilateral supraclavicular metastases: The University of Texas M.D. Anderson Cancer Center experience. J Clin Oncol 19:628-33, 2001. PMID: 11157012.
47. Cristofanilli M, Buzdar AU, Sneige N, Smith T, Wasaff B, Ibrahim N, Booser D, Rivera E, Murray JL, Valero V, Ueno N, Singletary ES, Hunt K, Strom E, McNeese M, Stelling C, Hortobagyi GN. Paclitaxel in the multimodality treatment for inflammatory breast carcinoma. Cancer 92:1775-82, 2001. PMID: 11745249.
48. Esmaeli B, Valero V, Ahmadi MA, Booser D. Canalicular stenosis secondary to docetaxel (taxotere): a newly recognized side effect. Ophthalmology 108:994-5, 2001. PMID: 11320034.
49. Ibrahim NK, Valero V, Rahman Z, Theriault RL, Walters RS, Buzdar AU, Booser DJ, Holmes FA, Murray JL, 3rd, Willey J, Bast R, Hortobagyi GN. Phase I-II vinorelbine (Navelbine) by continuous infusion in patients with metastatic breast cancer: cumulative toxicities limit dose escalation. Cancer Invest 19:459-66, 2001. PMID: 11458813.
50. Munster PN, Buzdar A, Dhingra K, Enas N, Ni L, Major M, Melemed A, Seidman A, Booser D, Theriault R, Norton L, Hudis C. Phase I study of a third-generation selective estrogen receptor modulator, LY353381.HCL, in metastatic breast cancer. J Clin Oncol 19:2002-9, 2001. PMID: 11283133.
51. Rivera E, Valero V, Syrewicz L, Rahman Z, Esteva FJ, Theriault RL, Rosales MM, Booser D, Murray JL, Bast RC, Jr, Hortobagyi GN. Phase I study of stealth liposomal doxorubicin in combination with gemcitabine in the treatment of patients with metastatic breast cancer. J Clin Oncol 19:1716-22, 2001. PMID: 11251001.
52. Booser DJ, Perez-Soler R, Cossum P, Esparza-Guerra L, Wu QP, Zou Y, Priebe W, Hortobagyi GN. Phase I study of liposomal annamycin. Cancer Chemother Pharmacol 46:427-32, 2000. PMID: 11127949.
53. Booser DJ, Walters RS, Holmes FA, Hortobagyi GN. Continuous-infusion high-dose leucovorin with 5-fluorouracil and cisplatin for relapsed metastatic breast cancer: a phase II study. Am J Clin Oncol 23:40-1, 2000. PMID: 10683074.
54. Hoff PM, Valero V, Buzdar AU, Singletary SE, Theriault RL, Booser DJ, Asmar L, Frye D, McNeese MD, Hortobagyi GN. Combined modality treatment of locally advanced breast carcinoma in elderly patients or patients with severe comorbid conditions using tamoxifen as the primary therapy. Cancer 88:2054-60, 2000. PMID: 10813717.
55. Hortobagyi GN, Buzdar AU, Theriault RL, Valero V, Frye D, Booser DJ, Holmes FA, Giralt S, Khouri I, Andersson B, Gajewski JL, Rondon G, Smith TL, Singletary SE, Ames FC, Sneige N, Strom EA, McNeese MD, Deisseroth AB, Champlin RE. Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma. J Natl Cancer Inst 92:225-33, 2000. PMID: 10655439.
56. Ibrahim NK, Valero V, Theriault RL, Willey J, Walters RS, Buzdar AU,Booser DJ, Hortobagyi GN. Phase I study of vinorelbine by 96-hour infusion in advanced metastatic breast cancer. Am J Clin Oncol 23:117-21, 2000. PMID: 10776969.
57. Rivera E, Holmes FA, Frye D, Valero V, Theriault RL, Booser DJ, Walters R, Buzdar AU, Dhingra K, Fraschini G, Hortobagyi GN. Phase II study of paclitaxel in patients with metastatic breast carcinoma refractory to standard chemotherapy. Cancer 89:2195-201, 2000. PMID: 11147589.
58. Berry DL, Theriault RL, Holmes FA, Parisi VM, Booser DJ, Singletary SE, Buzdar AU, Hortobagyi GN. Management of breast cancer during pregnancy using a standardized protocol. J Clin Oncol 17:855-61, 1999. PMID: 10071276.
59. Buzdar AU, Singletary SE, Theriault RL, Booser DJ, Valero V, Ibrahim N, Smith TL, Asmar L, Frye D, Manuel N, Kau SW, McNeese M, Strom E, Hunt K, Ames F, Hortobagyi GN. Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. J Clin Oncol 17:3412-7, 1999. PMID: 10550135.
60. Holmes FA, Valero V, Walters RS, Theriault RL, Booser DJ, Gibbs H, Fraschini G, Buzdar AU, Willey J, Frye D, Asmar L, Hortobagyi GN. Paclitaxel by 24-hour infusion with doxorubicin by 48-hour infusion as initial therapy for metastatic breast cancer: phase I results. Ann Oncol 10:403-11, 1999. PMID: 10370782.
61. Rivera E, Fraschini G, Esparza-Guerra L, Asmar L, Booser DJ, Buzdar AU, Theriault RL, Carrasco CM, Hortobagyi GN. Frontline arterial infusion chemotherapy for hepatic metastases in breast cancer patients. Cancer Therapeutics 1:44-9, 1999.
62. Valero V, Buzdar AU, Theriault RL, Azarnia N, Fonseca GA, Willey J, Ewer M, Walters RS, Mackay B, Podoloff D, Booser DJ, Lee LW, Hortobagyi GN. Phase II trial of liposome-encapsulated doxorubicin, cyclophosphamide, and fluorouracil as first-line therapy in patients with metastatic breast cancer. J Clin Oncol 17:1425-34, 1999. PMID: 10334527.
63. Valero V, Jones SE, Von Hoff DD, Booser DJ, Mennel RG, Ravdin PM, Holmes FA, Rahman Z, Schottstaedt MW, Erban JK, Esparza-Guerra L, Earhart RH, Hortobagyi GN, Burris HA, 3rd. A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer. J Clin Oncol 16:3362-8, 1998. PMID: 9779713.
64. Holmes FA, Madden T, Newman RA, Valero V, Theriault RL, Fraschini G, Walters RS, Booser DJ, Buzdar AU, Willey J, Hortobagyi GN. Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer. J Clin Oncol 14:2713-21, 1996. PMID: 8874332.
65. Buzdar AU, Singletary SE, Booser DJ, Frye DK, Wasaff B, Hortobagyi GN. Combined modality treatment of stage III and inflammatory breast cancer. MD Anderson Cancer Center experience. Surg Oncol Clin N Am 4:715-34, 1995. PMID: 8535907.
66. Dhingra K, Fritsche H, Murray JL, LoBuglio AF, Khazaeli MB, Kelley S, Tepper MA, Grasela D, Buzdar A, Valero V, Booser DJ, Whealin H, Collins TJ, Pursley JM, Hortobagyi G. Phase I clinical and pharmacologic study of suppression of human antimouse antibody response to monoclonal antibody L6 by deoxyspergualin. Cancer Res 55:3060-67, 1995.
67. Valero V, Buzdar A, Walters R, Willey J, Theriault RL, Fraschini G, Booser DJ, Fronseca G, Ewer M, Podolff D, Tanzola C, Gordon D, Hortobagyi GN. Phase II study of TLC-D-99 (liposomal doxorubicin), 5-FU, cycloposphamide in patients with metastatic breast cancer. Cancer Invest 13:29-31, 1995.
68. Walters RS, Theriault RL, Booser DJ, Esparza L, Hortobagyi GN. Phase II study of recombinant alpha-interferon (rIFN alpha) and continuous-infusion 5-fluorouracil in metastatic breast cancer. J Immunother Emphasis Tumor Immunol 18:185-7, 1995. PMID: 8770774.
69. Booser DJ, Hortobagyi GN. Anthracycline antibiotics in cancer therapy. Focus on drug resistance. Drugs 47(2):223-58, 1994. PMID: 7512899.
70. Buzdar AU, Hortobagyi GN, Frye D, Ho D, Booser DJ, Valero V, Holmes FA, Birmingham BK, Bui K, Yeh C, and Plourde Pl. Bioequivalence of 20-mg once-daily tamoxifen relative to 10-mg twice-daily tamoxifen regimens for breast cancer. J Clin Oncol 12:50-4, 1994. PMID: 8270984.
71. Buzdar AU, Kau S, Hortobagyi GN, Theriault RL, Booser DJ, Holmes FA, Walters R, Krakoff IH. Phase I trial of droloxifene in patients with metastatic breast cancer. Cancer Chemother Pharmacol 33:313-6, 1994. PMID: 8281625.
72. Dhingra K, Fritsche H, Murray JL, LoBuglio AF, Khazaeli MB, Kelley S, Tepper M, Greene D,Booser DJ, Buzdar A, et al. Suppression of human anti-mouse antibody response to murine monoclonal antibody L6 by deoxyspergualin: a phase I study. Adv Exp Med Biol 353:193-202, 1994. PMID: 7985538.
73. Dhingra K, Valero V, Gutierrez L, Theriault R, Booser DJ||, Holmes F, Buzdar A, Fraschini G, Hortobagyi G. Phase II study of deoxyspergualin in metastatic breast cancer. Invest New Drugs 12(3):235-41, 1994. PMID: 7896543.
74. Umsawasdi T, Valdivieso M, Booser DJ, Barkley HT, Jr, Ewer M, MacKay B, Dhingra HM, Murphy WK, Spitzer G, Chiuten DF, et al. Weekly doxorubicin versus doxorubicin every 3 weeks in cyclophosphamide, doxorubicin, and cisplatin chemotherapy for non-small cell lung cancer. Cancer 64:1995-2000, 1989. PMID: 2553235.
75. Umsawasdi T, Valdivieso M, Barkley HT, Jr, Chen T, Booser DJ, Chiuten DF, Dhingra HM, Murphy WK, Carr DT. Combined chemoradiotherapy in limited-disease, inoperable non-small cell lung cancer. Int J Radiat Oncol Biol Phys 14:43-8, 1988. PMID: 3335461.
76. Umsawasdi T, Valdivieso M, Barkley HT, Jr, Booser DJ, Chiuten DF, Murphy WK, Dhingra HM, Dixon CL, Farha P, Spitzer G, et al. Esophageal complications from combined chemoradiotherapy (cyclophosphamide + Adriamycin + cisplatin + XRT) in the treatment of non-small cell lung cancer. Int J Radiat Oncol Biol Phys 11:511-9, 1985. PMID: 3838297.
77. Dhingra HM, Valdivieso M, Booser DJ, Umsawasdi T, Carr DT, Chiuten DF, Murphy WK, Issell BF, Spitzer G, Farha P, et al. Chemotherapy for advanced adenocarcinoma and squamous cell carcinoma of the lung with etoposide and cisplatin. Cancer Treat Rep 68:671-3, 1984. PMID: 6538811.
78. Umsawasdi T, Valdivieso M, Chen TT, Barkley HT, Jr, Booser DJ, Chiuten DF, Dhingra HM, Murphy WK, Dixon CL, Farha P, Spitzer G and Carr DT. Role of elective brain irradiation during combined chemoradiotherapy for limited disease non-small cell lung cancer. J Neuroncol 2:253-9, 1984. PMID: 6389779.
79. Valdivieso M, Umsawasdi T, Spitzer G, Chiuten DF, DBooser DJ, Dhingra HM, Bodey GP. Phase II clinical evaluation of dihydroxyanthracenedione in patients with advanced lung cancer. Am J Clin Oncol 7:241-4, 1984. PMID: 6328968.
80. Valdivieso M, Farha P, Umsawasdi T, Booser DJ, Casimir MT, Chiuten DF, Dhingra HM, Dixon C, Murphy WK, Spitzer G, Dicke KA, Carr DT, Bodey GP. Antineoplastic Chemotherapy of Advanced Lung Cancer. Semin Resp Med 4:28-41, 1982.
81. Crookston JH, Yoshida A, Lin M, Booser DJ||. G6PD Toronto. Biochem Genet 8:259-65, 1973. PMID: 4701992.

Invited Articles

1. Booser DJ. Commentary: CYP2D6 Inhibition and Breast Cancer Recurrence in a Population-Based Study in Denmark. Breast Disease: A Year Book Quarterly 22:298, 2011.
2. Buzdar AU, Singletary SE,Booser DJ, Frye, DK, Wasaff B, Hortobagyi, GN. Combined modality treatment of stage III and inflammatory breast cancer. Surg Onc Clinc N Am 4:715-734, 1995.
3. Booser DJ, Hortobagyi GN. Anthracycline Antibiotics in Cancer Therapy. Focus on Drug Resistance. Drugs 47:223-58, 1994.
4. Booser DJ, Hortobagyi GN. Breast preservation after downstaging by induction chemotherapy for locally advanced breast cancer. Cancer Bull 45:517-22, 1993.
5. Holmes FA, Valero V, Walters RS, Theriault RL, Booser DJ||, Fraschini G, Buzdar AU, Frye D, Gibbs HR, Hortobagyi GN. The MD Anderson Cancer Center experience with Taxol in metastatic breast cancer. J Natl Cancer Inst Monogr:161-9, 1993. PMID: 7912522.
6. Booser DJ, Hortobagyi GN. Treatment of locally advanced breast cancer. Semin Oncol 19:278-85, 1992. PMID: 1609294.

Book Chapters

1. Buzdar A, Frye D, Ho D, Booser DJ, Valero V, Holmes F, Plourde P, Hortobagyi G. Bioavailability of nolvadex (Tamoxifen Citrate) as once-daily and twice-daily dosage regimens in patients with breast cancer. In: Adjuvant Therapy of Cancer VII. Lippincott, 237-39, 1993.